When was Megakaryo founded?

Megakaryo was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Megakaryo located?

Megakaryo is headquartered in Kyoto, Japan.

Who is the current CEO of Megakaryo?

Genjiro Miwa of Megakaryo. They are also an angel investors in 1 startup.

Is Megakaryo a funded company?

Megakaryo is a funded company, having raised a total of $91.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 2011.

When was the latest funding round of Megakaryo?

Megakaryo's latest funding was a $***** Series D round on Feb 17, 2020, with participation from 4 investors.

Where does Megakaryo rank among its competitors?

Megakaryo ranks 775th amongst 2533 active competitors, of which 876 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Megakaryo?

Megakaryo's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Megakaryo - 2026 Company Profile, Team, Funding & Competitors

Company Details

Megakaryon develops and commercializes the technology to produce and store platelets and red blood cells from iPS cell lines. The cell lines are used to develop blood products that can be supplied in a stable manner. The products can be used for blood transfusion and lower the dependence on blood donations. The company claims that it has obtained a patent for mass production of platelets from iPS cells.

Key Metrics

Founded Year

2011

Location

Kyoto, Japan

Stage

Series D

Total Funding

$91.5M in 5 rounds

Latest Funding Round

Series D, Feb 17, 2020, $*****

Investors

INCJ & 26 more

Ranked

775^th among 2533 active competitors

Similar Companies

STAR Therapeutics & 146 more

View Megakaryo's full profile

Megakaryo has raised a total funding of $91.5M over 5 rounds. Its first funding round was on Sep 2011. Its latest funding round was a Series D round on Feb 17, 2020 for $*****. 4 investors participated in its latest round. Megakaryo has 22 institutional investors and 5 angel investors.

Here is the list of recent funding rounds of Megakaryo:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 17, 2020	5066784	Series D	4708827	9445406	3680589	2150726
Dec 25, 2017	5468460	Series C	6761607	4846365	4891692	Shinsei Corporate Investment
Mar 23, 2015	5125643	Series B	2503506	4913339	INCJ & 8 more	8251758

Access funding benchmarks and valuations. Sign up today!

View details of Megakaryo's funding rounds and investors

The founders of Megakaryo is Genjiro Miwa.

Here are the details of Megakaryo's key team members:

Genjiro Miwa: CEO, President & Founder of Megakaryo. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of Megakaryo's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Megakaryo include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Megakaryo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
775th	Megakaryo 2011, Kyoto (Japan), Series D	Developer of induced pluripotent stem cells (iPS) for mass production of platelet products	$91.5M	SBI Investment, Japan Asia Investment & 25 others	41/100